TP53 and non-small cell lung carcinoma: NSCLC is known to harbor TP53 comutations [30], which we identified belonging to pathogenic and likely pathogenic categories in 21 cases (54% of the cohort patients, 48% in T790Mpos, and 64% in T790Mneg), yet they did not display a significant difference between both groups (Figure 2 and supplementary material, Table S2).